Curing leukemia ?
- document 1 document 2 document 3
- niveau 1 niveau 2 niveau 3
- audio 1 audio 2 audio 3
Descriptif
Non-pharmaceutical medical innovations and public health
The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress, detection of minimal residual disease precludes therapy termination in most TKI-receiving patients. CML has thus turned into a chronic illness, raising concerns about long-term safety, medication adherence and healthcare costs. Although treatment cessation may be feasible in few selected patients achieving deep molecular responses, a definitive cure remains elusive owing to the discovery that TKIs spare quiescent leukemic stem cells (LSC). Understanding mechanisms underlying LSC behavior in TKI-treated patients may provide important clues to develop an array of strategies that ensure the complete destruction of LSC reservoirs and thereby offer CML patients a definitive cure.
Cette présentation a été donnée dans le cadre du ScientificBRIO Day 2 organisé annuellement par le SIRIC BRIO et qui a pour but de réunirtous les acteurs du SIRIC BRIO et plus largement de la cancérologie à Bordeaux.
Thèmes
Notice
Dans la même collection
-
BRIO support to scientistsDessisDamien
BRIO management team was voluntarily built upon various competencies from different horizons (industry, charity…) to provide a broad skillset which aims at supporting the Bordeaux cancer research
-
-
Bordeaux Cancer InitiativeDessisDamienElustondoFrédéric
Translational science : how to move from biology to clinical applications Upon request of the University, the SIRIC was mandated to develop a transversal cancer axis at the University. The axis
-
A new preclinical model to test the response of breast cancer to genomically targeted therapyIggoRichard
Translational science : how to move from biology to clinical applications The rapid progress in next generation DNA sequencing technology (NGS) means it is now possible, in principle, to obtain a
-
Translational cancer genomics and proteomicsSleijferStefan
Translational science : how to move from biology to clinical applications Evaluation of cell-free DNA (cfDNA) is a very attractive tool to serve as “liquid biopsy” to define and establish
-
Cost-effectiveness analysis for decision making, illustrated theoryBénardAntoine
Interface technology/clinical/SHS/public health : case study interventional radiology In a health care system with limited resources, each euro invested in a health care intervention is no longer
-
Standardizing G8 evaluationSoubeyranPierre
Non-pharmaceutical innovations and public health Management of the frail elderly with cancer is a challenge. Beside a poor outcome as compared to younger subjects, physicians will face increased
-
-
Sociology contribution to understanding the (no)diffusion of a medical innovationGorryPhilippe
Interface technology/clinical/SHS/public health : case study interventional radiology We will present results of an undergoing study on the socioeconomic processes of recognition in oncology of a
-
BRIO's facts and figures, structuration projects : Axe Cancer, translational research centerUpdate …SoubeyranPierre
Update the implementation of BRIO Brio organisation is now fully up and running, and more than 100 research projects are currently active into the 6 integrated research programmes. In addition,
Sur le même thème
-
JPS 2017 / Dépistage en médecine générale
Journées des Professionnels de Santé 2017 Formation Médicale Continue des Médecins Généralistes >> Yves-Marie Vincent : Dépistage du cancer du sein >> Emmanuel Prothon et
-
-
A combined laser microdissection and mass spectrometry method for proteomic analysis of tissue sect…RaymondAnne-Aurélie
Clinical and biological samples : opportunities and challenges for translational research A challenge in oncology is to better define the tumor of the patient to study the pathology and of course
-
From the OR to clinical database... what for ? The example of UroCCRBernhardJean-Christophe
Clinical and biological samples : opportunities and challenges for translational research The UroCCR database was created to respond to the need on centralization and sharing of the multiple
-
Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomasLe Guyader-PeyrouSandra
Epidemiology and public health The principal aim of this thesis will describe the care pathway of diffuse large B cell lymphoma (DBCL) and follicular lymphoma (FL) in the general population and
-
Modelling prognostic capabilities of tumor size : application to colorectal cancerRondeauVirginie
Epidemiology and public health In oncology, the international WHO and RECIST criteria have allowed the standardization of tumor response evaluation in order to identify the time of disease
-
A new weapon against the tobacco industry : class action lawsuit using a novel epidemiologic param…SiemiatyckiJack
Epidemiology and public health Lawsuits against the tobacco industry, if successful, have the potential to compensate victims of smoking and to diminish the capacity of the tobacco industry to
-
How studying hematological malignancies subtypes may inform epidemiologic and clinical researchMonnereauAlain
Epidemiology and public health The aim of the talk entitled "How studying hematological malignancies (HM) subtypes may inform epidemiologic and clinical research" is to bring to the audience
-
Flash talk - Call for proposal FAC 2014ElustondoFrédéricWodrichHaraldFaustinBenjaminSaltelFrédéricCognetLaurent
Personalized breast cancer therapy based on viral functional assays to score pathway activity Harald Wodrich, University of Bordeaux State-of-the-art mass sequencing technology has paved the road
-
Sarcoma Database: a unique tool for research on mesenchymal tumorsCoindreJean-Michel
Clinical biology session The main sarcoma databases are the Conticabase (https://conticabase.sarcomabcb.org) and the ConticaGist (https://conticagist.sarcomabcb.org) with 18000 patients and which
-
BRIO supporting action to integrated cancer research in BordeauxMeoniPaolo
About BRIO Siric challenges and actions The success of BRIO’s approach and the realization of its potential impact on the translational research community in Bordeaux rely both on the efficient
-
BRIO strategic challenges and the implementation of a translational culture in BordeauxSoubeyranPierre
About BRIO Siric challenges and actions BRIO’s strategic objective is to strengthen Bordeaux’s leadership in Cancer Research through the creation of a dynamic cancer research community, the
